Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10

Suman Kanji, Manjusri Das, Reeva Aggarwal, Jingwei Lu, Matthew Joseph, Sujit Basu, Vincent J Pompili, Hiranmoy Das

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Nanofiber-expanded human umbilical cord blood-derived CD34. + cell therapy is under consideration for treating peripheral and cardiac ischemia. However, the therapeutic efficacy of nanofiber-expanded human umbilical cord blood-derived (NEHUCB) CD34. + cell therapy for wound healing and its mechanisms are yet to be established. Using an excision wound model in NOD/SCID mice, we show herein that NEHUCB-CD34. + cells home to the wound site and significantly accelerate the wound-healing process compared to vehicle-treated control. Histological analysis reveals that accelerated wound closure is associated with the re-epithelialization and increased angiogenesis. Additionally, NEHUCB-CD34. + cell-therapy decreases expression of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and NOS2A in the wound bed, and concomitantly increases expression of IL-10 compared to vehicle-treated control. These findings were recapitulated in vitro using primary dermal fibroblasts and NEHUCB-CD34. + cells. Moreover, NEHUCB-CD34. + cells attenuate NF-κB activation and nuclear translocation in dermal fibroblasts through enhanced secretion of IL-10, which is known to bind to NF-κB and suppress transcriptional activity. Collectively, these data provide novel mechanistic evidence of NEHUCB-CD34. + cell-mediated accelerated wound healing.

Original languageEnglish (US)
Pages (from-to)275-288
Number of pages14
JournalStem Cell Research
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Nanofibers
Cell- and Tissue-Based Therapy
Fetal Blood
Interleukin-10
Skin
Wounds and Injuries
Wound Healing
Fibroblasts
Re-Epithelialization
Inbred NOD Mouse
SCID Mice
Interleukin-1
Interleukin-6
Ischemia
Cytokines

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10. / Kanji, Suman; Das, Manjusri; Aggarwal, Reeva; Lu, Jingwei; Joseph, Matthew; Basu, Sujit; Pompili, Vincent J; Das, Hiranmoy.

In: Stem Cell Research, Vol. 12, No. 1, 01.01.2014, p. 275-288.

Research output: Contribution to journalArticle

Kanji, Suman ; Das, Manjusri ; Aggarwal, Reeva ; Lu, Jingwei ; Joseph, Matthew ; Basu, Sujit ; Pompili, Vincent J ; Das, Hiranmoy. / Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10. In: Stem Cell Research. 2014 ; Vol. 12, No. 1. pp. 275-288.
@article{fbedfc4f2a654d61b1df4f24106011f6,
title = "Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10",
abstract = "Nanofiber-expanded human umbilical cord blood-derived CD34. + cell therapy is under consideration for treating peripheral and cardiac ischemia. However, the therapeutic efficacy of nanofiber-expanded human umbilical cord blood-derived (NEHUCB) CD34. + cell therapy for wound healing and its mechanisms are yet to be established. Using an excision wound model in NOD/SCID mice, we show herein that NEHUCB-CD34. + cells home to the wound site and significantly accelerate the wound-healing process compared to vehicle-treated control. Histological analysis reveals that accelerated wound closure is associated with the re-epithelialization and increased angiogenesis. Additionally, NEHUCB-CD34. + cell-therapy decreases expression of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and NOS2A in the wound bed, and concomitantly increases expression of IL-10 compared to vehicle-treated control. These findings were recapitulated in vitro using primary dermal fibroblasts and NEHUCB-CD34. + cells. Moreover, NEHUCB-CD34. + cells attenuate NF-κB activation and nuclear translocation in dermal fibroblasts through enhanced secretion of IL-10, which is known to bind to NF-κB and suppress transcriptional activity. Collectively, these data provide novel mechanistic evidence of NEHUCB-CD34. + cell-mediated accelerated wound healing.",
author = "Suman Kanji and Manjusri Das and Reeva Aggarwal and Jingwei Lu and Matthew Joseph and Sujit Basu and Pompili, {Vincent J} and Hiranmoy Das",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.scr.2013.11.005",
language = "English (US)",
volume = "12",
pages = "275--288",
journal = "Stem Cell Research",
issn = "1873-5061",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10

AU - Kanji, Suman

AU - Das, Manjusri

AU - Aggarwal, Reeva

AU - Lu, Jingwei

AU - Joseph, Matthew

AU - Basu, Sujit

AU - Pompili, Vincent J

AU - Das, Hiranmoy

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Nanofiber-expanded human umbilical cord blood-derived CD34. + cell therapy is under consideration for treating peripheral and cardiac ischemia. However, the therapeutic efficacy of nanofiber-expanded human umbilical cord blood-derived (NEHUCB) CD34. + cell therapy for wound healing and its mechanisms are yet to be established. Using an excision wound model in NOD/SCID mice, we show herein that NEHUCB-CD34. + cells home to the wound site and significantly accelerate the wound-healing process compared to vehicle-treated control. Histological analysis reveals that accelerated wound closure is associated with the re-epithelialization and increased angiogenesis. Additionally, NEHUCB-CD34. + cell-therapy decreases expression of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and NOS2A in the wound bed, and concomitantly increases expression of IL-10 compared to vehicle-treated control. These findings were recapitulated in vitro using primary dermal fibroblasts and NEHUCB-CD34. + cells. Moreover, NEHUCB-CD34. + cells attenuate NF-κB activation and nuclear translocation in dermal fibroblasts through enhanced secretion of IL-10, which is known to bind to NF-κB and suppress transcriptional activity. Collectively, these data provide novel mechanistic evidence of NEHUCB-CD34. + cell-mediated accelerated wound healing.

AB - Nanofiber-expanded human umbilical cord blood-derived CD34. + cell therapy is under consideration for treating peripheral and cardiac ischemia. However, the therapeutic efficacy of nanofiber-expanded human umbilical cord blood-derived (NEHUCB) CD34. + cell therapy for wound healing and its mechanisms are yet to be established. Using an excision wound model in NOD/SCID mice, we show herein that NEHUCB-CD34. + cells home to the wound site and significantly accelerate the wound-healing process compared to vehicle-treated control. Histological analysis reveals that accelerated wound closure is associated with the re-epithelialization and increased angiogenesis. Additionally, NEHUCB-CD34. + cell-therapy decreases expression of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and NOS2A in the wound bed, and concomitantly increases expression of IL-10 compared to vehicle-treated control. These findings were recapitulated in vitro using primary dermal fibroblasts and NEHUCB-CD34. + cells. Moreover, NEHUCB-CD34. + cells attenuate NF-κB activation and nuclear translocation in dermal fibroblasts through enhanced secretion of IL-10, which is known to bind to NF-κB and suppress transcriptional activity. Collectively, these data provide novel mechanistic evidence of NEHUCB-CD34. + cell-mediated accelerated wound healing.

UR - http://www.scopus.com/inward/record.url?scp=84890208547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890208547&partnerID=8YFLogxK

U2 - 10.1016/j.scr.2013.11.005

DO - 10.1016/j.scr.2013.11.005

M3 - Article

VL - 12

SP - 275

EP - 288

JO - Stem Cell Research

JF - Stem Cell Research

SN - 1873-5061

IS - 1

ER -